TY - JOUR
T1 - Application of Magnetic Nanoparticles for Rapid Detection and In Situ Diagnosis in Clinical Oncology
AU - Onishi, Tatsuya
AU - Mihara, Kisyo
AU - Matsuda, Sachiko
AU - Sakamoto, Satoshi
AU - Kuwahat, Akihiro
AU - Sekino, Masaki
AU - Kusakabe, Moriaki
AU - Handa, Hiroshi
AU - Kitagawa, Yuko
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Screening, monitoring, and diagnosis are critical in oncology treatment. However, there are limitations with the current clinical methods, notably the time, cost, and special facilities required for radioisotope-based methods. An alternative approach, which uses magnetic beads, offers faster analyses with safer materials over a wide range of oncological applications. Magnetic beads have been used to detect extracellular vesicles (EVs) in the serum of pancreatic cancer patients with statistically different EV levels in preoperative, postoperative, and negative control samples. By incorporating fluorescence, magnetic beads have been used to quantitatively measure prostate-specific antigen (PSA), a prostate cancer biomarker, which is sensitive enough even at levels found in healthy patients. Immunostaining has also been incorporated with magnetic beads and compared with conventional immunohistochemical methods to detect lesions, the results suggest that immunostained magnetic beads could be used for pathological diagnosis during surgery. Furthermore, magnetic nanoparticles, such as superparamagnetic iron oxide nanoparticles (SPIONs), can detect sentinel lymph nodes in breast cancer in a clinical setting, as well as those in gallbladder cancer in animal models, in a surgery-applicable timeframe. Ultimately, recent research into the applications of magnetic beads in oncology suggests that the screening, monitoring, and diagnosis of cancers could be improved and made more accessible through the adoption of this technology.
AB - Screening, monitoring, and diagnosis are critical in oncology treatment. However, there are limitations with the current clinical methods, notably the time, cost, and special facilities required for radioisotope-based methods. An alternative approach, which uses magnetic beads, offers faster analyses with safer materials over a wide range of oncological applications. Magnetic beads have been used to detect extracellular vesicles (EVs) in the serum of pancreatic cancer patients with statistically different EV levels in preoperative, postoperative, and negative control samples. By incorporating fluorescence, magnetic beads have been used to quantitatively measure prostate-specific antigen (PSA), a prostate cancer biomarker, which is sensitive enough even at levels found in healthy patients. Immunostaining has also been incorporated with magnetic beads and compared with conventional immunohistochemical methods to detect lesions, the results suggest that immunostained magnetic beads could be used for pathological diagnosis during surgery. Furthermore, magnetic nanoparticles, such as superparamagnetic iron oxide nanoparticles (SPIONs), can detect sentinel lymph nodes in breast cancer in a clinical setting, as well as those in gallbladder cancer in animal models, in a surgery-applicable timeframe. Ultimately, recent research into the applications of magnetic beads in oncology suggests that the screening, monitoring, and diagnosis of cancers could be improved and made more accessible through the adoption of this technology.
KW - Extracellular vesical quantification
KW - In situ diagnosis
KW - Magnetic nanoparticles
KW - Pathological diagnosis
KW - Presurgical screening
KW - Rapid detection
KW - Sentinel node mapping
UR - http://www.scopus.com/inward/record.url?scp=85123065058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123065058&partnerID=8YFLogxK
U2 - 10.3390/cancers14020364
DO - 10.3390/cancers14020364
M3 - Article
AN - SCOPUS:85123065058
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 2
M1 - 364
ER -